Literature DB >> 15482757

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.

David W Schmidt1, Donald B Maier, John C Nulsen, Claudio A Benadiva.   

Abstract

OBJECTIVE: The lowest effective hCG dose in high responders during IVF-embryo transfer (ET) has not been established. This study was performed to confirm that a dose of 3,300 IU is sufficient to provide adequate oocyte maturation and fertilization.
DESIGN: Retrospective review of IVF clinical data.
SETTING: Infertility center at a tertiary care university. PATIENT(S): Ninety-four IVF cycles were analyzed from high responders based on peak E(2) levels. Demographics were compared including age, diagnosis, and stimulation protocol. INTERVENTION(S): On the day of hCG administration, if E(2) levels were >/=2,500 but <4,000 pg/mL, patients received 5,000 IU (group A). For levels between 4,000 pg/mL and 5,500 IU pg/mL, they received 3,300 IU (group B). MAIN OUTCOME MEASURE(S): Number of oocytes retrieved, proportion of mature oocytes, fertilization rates, chemical and clinical pregnancy rates (PR). The incidence and severity of ovarian hyperstimulation syndrome (OHSS) was also analyzed. RESULT(S): Mean ages were 35.4 +/- 0.7 and 33.2 +/- 0.7 for groups A and B, respectively. Peak E(2) levels differed significantly (2,907 +/- 76 vs. 4,260 +/- 129 pg/mL), as well as the mean number of eggs retrieved (15.9 +/- 0.9 vs. 20.3 +/- 1.2). Proportion of mature eggs (81.6% vs. 81.9%), fertilization rate (70.5% vs. 68.7%), chemical PR (58.7% vs. 58.7%), and clinical PR (50.0% vs. 43.5%) were similar. There was no difference in the incidence of mild, moderate, or severe OHSS. CONCLUSION(S): A reduced hCG dose of 3,300 IU results in a similar proportion of mature eggs, similar fertilization rates, and similar PRs compared to 5,000 IU. Reducing the dose of hCG does not eliminate the risk of OHSS in a high-risk group.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482757     DOI: 10.1016/j.fertnstert.2004.03.055

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  17 in total

1.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

2.  The time interval between hCG priming and oocyte retrieval in ART program: a meta-analysis.

Authors:  Wei Wang; Xue-Hong Zhang; Wei-Hua Wang; Ya-Li Liu; Li-Hui Zhao; Shi-Long Xue; Ke-Hu Yang
Journal:  J Assist Reprod Genet       Date:  2011-07-27       Impact factor: 3.412

Review 3.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

Review 4.  Ovarian hyperstimulation syndrome: pathophysiology and prevention.

Authors:  Carolina O Nastri; Rui A Ferriani; Isa A Rocha; Wellington P Martins
Journal:  J Assist Reprod Genet       Date:  2010-02-06       Impact factor: 3.412

5.  Gene expression profiling of granulosa cells from PCOS patients following varying doses of human chorionic gonadotropin.

Authors:  Serdar Coskun; Hasan H Otu; Khalid A Awartani; Laila A Al-Alwan; Saad Al-Hassan; Hend Al-Mayman; Namik Kaya; Mehmet S Inan
Journal:  J Assist Reprod Genet       Date:  2013-02-05       Impact factor: 3.412

6.  Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management.

Authors:  Michael M Alper; Laura P Smith; Eric Scott Sills
Journal:  J Exp Clin Assist Reprod       Date:  2009-06-10

7.  GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Ivy Maina; Clarisa Gracia; Anuja Dokras
Journal:  J Assist Reprod Genet       Date:  2016-06-27       Impact factor: 3.412

8.  Minimum dose of hCG to trigger final oocyte maturation and prevent OHSS in a long GnRHa protocol.

Authors:  Xin Chen; Shi-Ling Chen; Yu-Xia He; De-Sheng Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

9.  New algorithm for OHSS prevention.

Authors:  Evangelos G Papanikolaou; Peter Humaidan; Nikos Polyzos; Sofia Kalantaridou; Sahar Kol; Claudio Benadiva; Herman Tournaye; Basil Tarlatzis
Journal:  Reprod Biol Endocrinol       Date:  2011-11-03       Impact factor: 5.211

Review 10.  Untapped Reserves: Controlling Primordial Follicle Growth Activation.

Authors:  Amanda Kallen; Alex J Polotsky; Joshua Johnson
Journal:  Trends Mol Med       Date:  2018-02-13       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.